Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709371 · ClinicalTrials.gov registry record · Phase 2
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
A Phase 2 study of Obesity, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 729
- Enrollment target
- 20
- Study locations
NCT00709371: Completed Phase 2 study of Obesity, sponsored by Orexigen Therapeutics.
NCT00709371 is a Phase 2 study of Obesity that has completed, run by Orexigen Therapeutics. The registered enrollment target is 729 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00709371, a Phase 2 study of Obesity, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 729 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
Conditions Studied
Interventions
- DRUG Zonisamide SR placebo/ bupropion SR placebo
- DRUG Zonisamide SR placebo/ bupropion SR 360 mg/day
- DRUG Zonisamide SR 120 mg/day/ bupropion SR placebo
- DRUG Zonisamide SR 360 mg/day/ bupropion SR placebo
- DRUG Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
Study Locations (20)
Massachusetts
- Nutrition and Weight Management Center, Boston Medical Center - Boston
- FutureCare Studies - Springfield
North Carolina
- Internal Medicine Associates of Charlotte - Charlotte
- Wake Research Associates, LLC - Raleigh
Alabama
- SelfCenter, PC - Fairhope
California
- Nutrition and Metabolic Research - La Jolla
Colorado
- Center for Human Nutrition/UCD - Denver
Florida
- Miami Research Associates - Miami
Georgia
- CSRA Partners in Health, Inc. - Augusta
Illinois
- Radiant Research, Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00709371 record still lists
NCT00709371 is an interventional study that assigns participants to a tested intervention. The registered 729 participants enrollment target is mid-sized for trials with a published cap, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Zonisamide SR placebo/ bupropion SR placebo is the first listed.
NCT00709371 names 20 study sites across 18 states, led by Massachusetts, North Carolina, Alabama.
Frequently Asked Questions
What is clinical trial NCT00709371 about?
NCT00709371 is a clinical study titled "Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity". The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
What is the current status of trial NCT00709371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 729 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00709371 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00709371?
The interventions under investigation include: Zonisamide SR placebo/ bupropion SR placebo (DRUG), Zonisamide SR placebo/ bupropion SR 360 mg/day (DRUG), Zonisamide SR 120 mg/day/ bupropion SR placebo (DRUG), Zonisamide SR 360 mg/day/ bupropion SR placebo (DRUG), Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day (DRUG).
Who is sponsoring clinical trial NCT00709371?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00709371 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00709371's enrollment target sits among peer trials
729 102nd of 1053 higher than 952 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia